Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04570332 | BO-112 With Pembrolizumab in Unresectable Malignant Melanoma(SPOTLIGHT203) | completed | Phase 2 | 42 | Highlight TherapeuticsINDUSTRY | 2 | Nov 26, 2025 | clinicaltrials |
| NCT01473004 | SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | completed | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT01397708 | Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma | completed | Phase 1 / Phase 2 | 26 | Alaunos TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04700072 | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 56 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Oct 28, 2025 | clinicaltrials |
| NCT04208958 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer(ConsortiumIO) | completed | Phase 1 / Phase 2 | 56 | Vedanta Biosciences, Inc.INDUSTRY | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT00244816 | Taxoprexin® Treatment for Advanced Eye Melanoma | completed | Phase 2 | 22 | American Regent, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT00249262 | Taxoprexin Treatment for Advanced Skin Melanoma | completed | Phase 2 | 30 | American Regent, Inc.INDUSTRY | 0 | Sep 26, 2025 | clinicaltrials |
| NCT04577807 | LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma | completed | Phase 2 | 27 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04988841 | Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma(PICASSO) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05578872 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | completed | Phase 1 / Phase 2 | 29 | Anaveon AGINDUSTRY | 5 | Aug 26, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT02681549 | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 41 | Yale UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02553642 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05304546 | Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma(MK3475-C01) | completed | Phase 2 | 1 | Dr. Ronnie ShapiraOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05116202 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | completed | Phase 1 / Phase 2 | 110 | Hoffmann-La RocheINDUSTRY | 5 | Jul 18, 2025 | clinicaltrials |
| NCT04493203 | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | completed | Phase 2 | 31 | Yana NajjarOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT01378975 | A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 10 | Jun 25, 2025 | clinicaltrials |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | completed | Phase 1 / Phase 2 | 41 | BiogenINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT03898908 | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain(EBRAIN-MEL) | completed | Phase 2 | 48 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT00661622 | Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF | completed | Phase 2 | 53 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03618641 | CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | completed | Phase 2 | 34 | Diwakar DavarOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04993677 | A Study of SEA-CD40 Given With Other Drugs in Cancers | completed | Phase 2 | 77 | Seagen Inc.INDUSTRY | 6 | May 11, 2025 | clinicaltrials |
| NCT02875132 | Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma | completed | Phase 2 | 9 | Chinese University of Hong KongOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT01355120 | THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease(DeCOG) | completed | Phase 2 | 171 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT02523313 | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED | completed | Phase 2 | 167 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT02902029 | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(ImmunoCobiVem) | completed | Phase 2 | 186 | University Hospital, EssenOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 191 | Syndax PharmaceuticalsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04330430 | Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease(NIVEC) | completed | Phase 2 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04133948 | Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma(DONIMI) | completed | Phase 1 / Phase 2 | 44 | The Netherlands Cancer InstituteOTHER | 2 | Mar 10, 2025 | clinicaltrials |
| NCT05340621 | NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) | completed | Phase 1 / Phase 2 | 36 | OnKure, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04417530 | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma | completed | Phase 2 | 22 | Aura BiosciencesINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03047928 | Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 48 | Inge Marie SvaneOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02819843 | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | completed | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT02936388 | Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis(SirTac) | completed | Phase 2 | 108 | Charite University, Berlin, GermanyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT02500576 | Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT01902173 | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02872259 | BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma | completed | Phase 1 / Phase 2 | 74 | Haukeland University HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04382664 | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | completed | Phase 2 | 156 | Ultimovacs ASAINDUSTRY | 4 | Jan 14, 2025 | clinicaltrials |
| NCT01884961 | Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2(IL2HD) | completed | Phase 2 | 46 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03033576 | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2025 | clinicaltrials |
| NCT01973322 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study(ABSIDE) | completed | Phase 2 | 34 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05031494 | A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers | completed | Phase 2 | 40 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 2 | Jan 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 26, 2025source: clinicaltrials